



Financial Tear Sheet

Corporate Profile

Rigel's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

Date	Title
06/22/17	Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
06/19/17	FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP

Stock Performance

RIGL (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.81
Change (%)	-0.03 (1.06%)
Volume	1,055,768
Data as of 06/28/17 4:00 p.m. ET Refresh quote	



Data provided by Nasdaq. Minimum 15 minutes delayed.

SEC Filings

Filing Date	Form
05/30/17	424B5

Primary IR Contact

Ryan Maynard
CFO
Phone: (650) 624-1284

05/30/17

8-K

E-mail: invrel@rigel.com